4552
JCR Pharmaceuticals Co.,Ltd.
ＪＣＲファーマ
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
51,082
Mar 2023
34,343
Mar 2024
42,871
Mar 2025
33,072
Mar 2026
40,319
Operating profit(million JPY)
Mar 2022
19,933
Mar 2023
4,975
Mar 2024
7,531
Mar 2025
-6,219
Mar 2026
555
Operating profit margin(%)
Mar 2022
39.02
Mar 2023
14.49
Mar 2024
17.57
Mar 2025
-18.8
Mar 2026
1.38
Profit before tax(million JPY)
Mar 2022
19,404
Mar 2023
5,412
Mar 2024
7,244
Mar 2025
-5,983
Mar 2026
3,224
Profit(million JPY)
Mar 2022
14,507
Mar 2023
3,772
Mar 2024
5,507
Mar 2025
-4,460
Mar 2026
2,178
Total assets(million JPY)
Mar 2022
97,134
Mar 2023
94,937
Mar 2024
102,226
Mar 2025
104,849
Mar 2026
109,236
Cash and cash equivalents(million JPY)
Mar 2022
30,733
Mar 2023
13,278
Mar 2024
18,756
Mar 2025
13,196
Mar 2026
14,007
Cash flows from operating activities(million JPY)
Mar 2022
9,289
Mar 2023
-5,500
Mar 2024
9,312
Mar 2025
-5,791
Mar 2026
-135
Cash flows from investing activities(million JPY)
Mar 2022
-3,250
Mar 2023
-15,002
Mar 2024
-2,690
Mar 2025
-9,569
Mar 2026
-12,504
Cash flows from financing activities(million JPY)
Mar 2022
-2,179
Mar 2023
1,948
Mar 2024
-2,031
Mar 2025
9,736
Mar 2026
13,305
Return on equity(%)
Mar 2022
32.9
Mar 2023
7.4
Mar 2024
10.3
Mar 2025
-8.7
Mar 2026
4.6
Equity ratio(%)
Mar 2022
51.8
Mar 2023
54.2
Mar 2024
54.2
Mar 2025
45.1
Mar 2026
42.9
Earnings per share(JPY per share)
Mar 2022
117.26
Mar 2023
30.35
Mar 2024
44.13
Mar 2025
-36.02
Mar 2026
17.87
Net assets per share(JPY per share)
Mar 2022
406.57
Mar 2023
412.11
Mar 2024
443.62
Mar 2025
387.95
Mar 2026
384.19
Dividend per share(JPY per share)
Mar 2022
22
Mar 2023
20
Mar 2024
20
Mar 2025
20
Mar 2026
20
Payout ratio(%)
Mar 2022
18.76
Mar 2023
65.9
Mar 2024
45.32
Mar 2025
-
Mar 2026
111.92
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.